Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
Tefferi
A
A
Lasho
T L
TL
Mesa
R A
RA
Pardanani
A
A
Ketterling
R P
RP
Hanson
C A
CA
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D017354:Point Mutation / Q000235:genetics*; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000235:genetics; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000077269:Lenalidomide